Also known as (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, example 14 [US8865698 B2], larotrectinib (proposed INN), LOXO-101, ARRY-470
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
~3 min read
{{Infobox drug | image = Larotrectinib.svg | image_class = skin-invert-image | alt = | caption =
| pronounce = | tradename = Vitrakvi | Drugs.com = | MedlinePlus = a619006 | DailyMedID = Larotrectinib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth, oropharyngeal | class = | ATC_prefix = L01 | ATC_suffix = EX12
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).